The recipient was Tim Andrews, a 66-year-old New Hampshire resident who had end-stage kidney disease and was on dialysis for ...
Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from ...
However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...
The Trump administration’s overarching message to the legions of people powering the federal government is simple: Leave.
The more complex and labor-intensive esoteric tests are reimbursed at a higher rate and often outsourced by hospitals to independent labs. Labcorp is funneling resources to broaden its menu of complex ...
Following a recall of grounding pads produced by Megadyne, a machinery industry company, the FDA is notifying veterinarians ...
Former federal health official Gerald Parker is Trump's choice to lead the White House's pandemic preparedness office.
That wisdom from one of our nation’s founders is clearly lost on President Trump and his chief unelected henchman, Elon Musk, ...
A clinical trial comparing a one-page medication handout proposed by the U.S. Food and Drug Administration (FDA) with an ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.
The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback